The Food and Drug Administration (FDA) has approved Kynmobi™ (apomorphine hydrochloride; Sunovion) for the acute, intermittent treatment of off episodes in patients with Parkinson disease (PD).
Long-term effect of eculizumab in patients with neuromyelitis optica spectrum disorder warrants further study, since there was no significant between-group difference in measures of disability progression.
Investigators found that OV101 (gaboxadol) was clinically beneficial in adults and adolescents with Angelman syndrome.
